Returns | 1W : -0.1% , 1M : -9%,1Y : 48.1% |
LT :   |
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
SAKAR HEALTHCARE LTD | -0.1% | -9% | 48.1% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 0% | 3% | 58.9% |
DR REDDYS LABORATORIES LTD | -0.8% | -3.2% | 43.9% |
DIVIS LABORATORIES LTD | 0.4% | 2.7% | 57.2% |
CIPLA LTD | -0.2% | -4.4% | 86.2% |
BIOCON LTD | 2.6% | 6.3% | 30.6% |
AUROBINDO PHARMA LTD | 2% | -3.6% | 67.6% |
LUPIN LTD | 1.2% | 1.5% | 52.2% |
TORRENT PHARMACEUTICALS LTD | 0.5% | -6.4% | 8% |
Ratio | Value |
---|---|
P/E P/B P/S |
14.74
P/E Calculated based on EPS of 6.43
[ Mar2020 - Standalone Results ] 1.74
P/B Calculated based on Book Value of 54.35
[ Mar2020 - Standalone Results ] 1.7
P/S Calculated based on Revenues of 86.741 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA 70% 90% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |